Recently, Schurman et al. suggested that γ-H2A.X may be a biomarker for human morbidity in age-related diseases [21]: the number of γ-H2A.X foci in human blood cells was higher in the middle-aged subjects (50–59 years) than in the younger subjects (35–49 years) and the number of γ-H2AX foci/cell in patients with hypertension was 36% higher than those in nonhypertensive patients, particularly among those ≥57 years [21]. The gene discussed is H2AX; the disease is hypertensive disorder.